Alliances
Sanofi will study its SAR444245 in combination with Immunocore’s KIMMTRAK in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers.
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.
Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
The FDA has issued special designations that could improve the lives of millions with recurrent glioblastoma or hemophilia diagnoses.
The initiative, a partnership between non-profit biotech company n-Lorem and Columbia University, focuses on developing personalized experimental ASO medicines for nano-rare ALS patients.
Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday.
PRESS RELEASES